Skip to main content

Table 3 Correlations between changes in β-OHB, blood pressure and vascular parameters

From: Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure

 

Empa Δβ-OHB

Placebo Δβ-OHB

Δ Resting peripheral systolic BP

r = 0.458

r = − 0.336

p = 0.011

p = 0.203

Δ Resting peripheral diastolic BP

r = 0.365

r = − 0.162

p = 0.047

p = 0.548

Δ Resting peripheral pulse pressure

r = 0.471

r = − 0.087

p = 0.009

p = 0.749

Δ Central systolic BP

r = 0.470

r = − 0.413

p = 0.009

p = 0.112

Δ Central pulse pressure

r = 0.391

r = − 0.266

p = 0.033

p = 0.320

Δ Forward pulse pressure height

r = 0.451

r = 0.086

p = 0.012

p = 0.752

Δ Resting pulse pressure height

r = 0.217

r = − 0.342

p = 0.250

p = 0.194

Δ Systolic 24 h ambulatory BP

r = 0.321

r = 0.141

p = 0.069

p = 0.630

Δ Diastolic 24 h ambulatory BP

r = 0.516

r = 0.195

p = 0.002

p = 0.504

Δ Heart rate

r = 0.188

r = 0.439

p = 0.320

p = 0.089

  1. Δ: change between baseline and after 12 weeks of treatment, β-OHB: β-hydroxybutyrate; empa: empagliflozin; BP: blood pressure